Clinical trial
Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone…
NCT00073164 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00073164 |
|---|---|
| Title | Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia |
| Official title | A Study of the Safety and Efficacy of Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone |
| Enrollment | 400 |
| Start date | Jul 1, 2003 |
| First posted | Nov 18, 2003 |
| Last update posted | Aug 4, 2006 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: